



## Achilles Therapeutics to Present at Upcoming Investor Conferences

September 2, 2021

LONDON, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing precision T cell therapies to treat solid tumors, today announced that management will present at the following investor conferences in September.

- **Wells Fargo Virtual Healthcare Conference** on Friday, September 10, 2021 at 10:40am ET / 3:40pm UK
- **H.C. Wainwright 23rd Annual Global Investment Conference** available beginning Monday, September 13, 2021 at 7:00am ET / 12:00pm UK
- **Oppenheimer Fall Healthcare Life Sciences & MedTech Summit** on Wednesday, September 22, 2021 at 8:15am ET / 1:15pm UK

A live and archived webcast of the presentations will be available in the [Events & Presentations](#) section of the [Achilles website](#).

### About Achilles Therapeutics

Achilles is a clinical-stage biopharmaceutical company developing precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. The Company has two ongoing Phase I/IIa trials, the CHIRON trial in patients with advanced non-small cell lung cancer (NSCLC) and the THETIS trial in patients with recurrent or metastatic melanoma. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUS™ bioinformatics platform, to identify clonal neoantigens specific to that patient, and then develop precision T cell-based product candidates specifically targeting those clonal neoantigens.

### Further information:

#### Lee M. Stern – VP, IR & External Communications

+1 (332) 373-2634

[l.stern@achillestx.com](mailto:l.stern@achillestx.com)

#### Consilium Strategic Communications

Mary-Jane Elliott, Sukaina Virji, Melissa Gardiner

+44 (0) 203 709 5000

[achillestx@consilium-comms.com](mailto:achillestx@consilium-comms.com)